PEP trial. Pulmonary Embolism Prevention.
Smulders
Y
Y
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D002423:Cause of Death; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000517:prevention & control*; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014662:Vasoconstrictor Agents; D013928:Thromboxane A2; D001241:Aspirin